Urocortin III (mouse) (free acid) (trifluoroacetate salt)
目录号 : GC45590
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Mouse urocortin III shares 90, 40, 37, and 18% identity to human urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. It is expressed in the hypothalamus, brainstem, lateral septum (LS)/bed nucleus of stria terminalis (BnST) in the CNS and the small intestine, pancreatic β-cells, and skin in the periphery in mice. Urocortin III selectively binds to type 2 CRF receptors (Kis = 5, 1.8, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.073 and 0.08 nM, respectively) as well as in cultured anterior pituitary cells expressing endogenous CRF2β. In vivo, urocortin III (2 μg, i.p.) accelerates metamorphosis of S. hammondii tadpoles.2 Urocortin III (20 μg, i.c.v.) increases exploration in the open field test and decreases latency to enter the lit compartment in the dark-light emergence test in mice, indicating anxiolytic-like activity, and mRNA expression is increased in mouse brain in response to restraint.3 It is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro and in vivo in wild-type mice, however, it is depleted from β-cells in mouse and macaque models of type 2 diabetes, suggesting a role in glycemic control.4
References
1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).
2. Okada, R., Miller, M.F., Yamamoto, K., et al. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland. Gen. Comp. Endocrinol. 150(3), 437-444 (2007).
3. Sadhu, C., Dick, K., Tino, W.T., et al. Selective role of PI3Kδ in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 308(4), 764-769 (2003).
4. van der Meulen, T., Donaldson, C.J., CÁceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).
Cas No. | SDF | ||
分子式 | C186H311N51O53S2.XCF3COOH | 分子量 | 4173.9 |
溶解度 | Formic Acid: 1 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.2396 mL | 1.1979 mL | 2.3958 mL |
5 mM | 0.0479 mL | 0.2396 mL | 0.4792 mL |
10 mM | 0.024 mL | 0.1198 mL | 0.2396 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。